CD33 and glioma: Therefore, we assessed the expression of the different Siglec family members on sorted M-MDSCs (CD33+ MHC IIlow/− CD14+) and PMN-MDSCs (CD33+ MHC IIlow/− CD15+) from the blood of glioma patients (Fig. 1a).